Symbols / PHVS
PHVS Chart
About
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.82B |
| Enterprise Value | 1.49B | Income | -163.72M | Sales | — |
| Book/sh | 5.67 | Cash/sh | 5.07 | Dividend Yield | — |
| Payout | 0.00% | Employees | 118 | IPO | — |
| P/E | — | Forward P/E | -8.68 | PEG | — |
| P/S | — | P/B | 4.94 | P/C | — |
| EV/EBITDA | -8.89 | EV/Sales | — | Quick Ratio | 12.67 |
| Current Ratio | 12.86 | Debt/Eq | 0.18 | LT Debt/Eq | — |
| EPS (ttm) | -3.42 | EPS next Y | -3.23 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-04-06 | ROA | -32.07% |
| ROE | -53.76% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 64.96M |
| Shs Float | 33.47M | Short Float | 1.38% | Short Ratio | 3.65 |
| Short Interest | — | 52W High | 29.80 | 52W Low | 11.51 |
| Beta | -2.79 | Avg Volume | 290.40K | Volume | 8.42K |
| Target Price | $46.41 | Recom | Strong_buy | Prev Close | $27.95 |
| Price | $28.01 | Change | 0.21% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$46.41
Mean price target
2. Current target
$28.01
Latest analyst target
3. DCF / Fair value
$-21.10
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$28.01
Low
$30.34
High
$77.87
Mean
$46.41
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-04 | main | Oppenheimer | Outperform → Outperform | $50 |
| 2025-12-04 | main | Guggenheim | Buy → Buy | $39 |
| 2025-12-04 | main | Morgan Stanley | Overweight → Overweight | $41 |
| 2025-12-04 | main | B of A Securities | Neutral → Neutral | $30 |
| 2025-12-03 | reit | HC Wainwright & Co. | Buy → Buy | $60 |
| 2025-11-14 | main | Morgan Stanley | Overweight → Overweight | $37 |
| 2025-11-13 | main | Wedbush | Outperform → Outperform | $30 |
| 2025-11-13 | reit | HC Wainwright & Co. | Buy → Buy | $60 |
| 2025-10-15 | init | HC Wainwright & Co. | — → Buy | $60 |
| 2025-10-09 | up | B of A Securities | Underperform → Neutral | $27 |
| 2025-08-13 | main | JMP Securities | Market Outperform → Market Outperform | $52 |
| 2025-06-05 | reit | Wedbush | Outperform → Outperform | $27 |
| 2025-05-14 | main | Cantor Fitzgerald | Overweight → Overweight | $25 |
| 2025-05-14 | main | Wedbush | Outperform → Outperform | $27 |
| 2025-04-29 | init | Cantor Fitzgerald | — → Overweight | $28 |
| 2025-03-03 | reit | Citizens Capital Markets | Market Outperform → Market Outperform | $55 |
| 2025-01-31 | main | JMP Securities | Market Outperform → Market Outperform | $55 |
| 2024-09-19 | init | Jones Trading | — → Buy | $46 |
| 2024-09-06 | main | Oppenheimer | Outperform → Outperform | $42 |
| 2024-07-03 | main | Oppenheimer | Outperform → Outperform | $38 |
- Pharvaris N.V. (PHVS) Stock Analysis: A 65% Upside Potential In The Biotech Sector - DirectorsTalk Interviews Fri, 20 Feb 2026 08
- Pharvaris (PHVS): Evaluating Valuation Premium After Recent Share Price Momentum - Yahoo Finance hu, 13 Nov 2025 08
- PHVS Stock Jumps After Phase 3 Trial Shows Rapid Symptom Relief For Oral HAE Treatment - Stocktwits Wed, 03 Dec 2025 08
- Pharvaris (Nasdaq: PHVS) posts positive RAPIDe-3 data, targets 1H 2026 NDA filing - Stock Titan Wed, 03 Dec 2025 08
- What Pharvaris (PHVS)'s New Deucrictibant Phase 3 and Platform Data Wave Means For Shareholders - simplywall.st Wed, 11 Feb 2026 08
- Pharvaris stock surges after positive HAE treatment study results - Investing.com Wed, 03 Dec 2025 08
- Biotechs Duke It Out In A Genetic Disease — And Both Surge - Investor's Business Daily Wed, 03 Dec 2025 08
- Understanding the Setup: (PHVS) and Scalable Risk - Stock Traders Daily Sun, 15 Feb 2026 17
- Pharvaris: Biotech With De-Risked Phase 3 Readout Coming, Initiating With A Buy Rating - Seeking Alpha Sun, 23 Nov 2025 08
- A Look At Pharvaris (PHVS) Valuation As Deucrictibant Advances With New Phase 3 And Phase 2 Data - Sahm ue, 17 Feb 2026 17
- New Analyst Forecast: $PHVS Given $30 Price Target - Quiver Quantitative hu, 04 Dec 2025 08
- This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy? - The Motley Fool ue, 09 Dec 2025 08
- Pharvaris (Nasdaq: PHVS) shows 92.4% HAE attack reduction with oral deucrictibant - Stock Titan Mon, 10 Nov 2025 08
- Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals - Yahoo Finance hu, 04 Dec 2025 08
- Guggenheim raises Pharvaris stock price target to $39 on positive trial data - Investing.com hu, 04 Dec 2025 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 2.03M | -804.10K | 2.86M | 2.94M |
| TaxRateForCalcs | 0.26 | 0.26 | 0.26 | 0.25 |
| NormalizedEBITDA | -153.29M | -93.54M | -97.66M | -65.82M |
| TotalUnusualItems | 7.87M | -3.12M | 11.10M | 11.76M |
| TotalUnusualItemsExcludingGoodwill | 7.87M | -3.12M | 11.10M | 11.76M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -134.22M | -100.88M | -76.33M | -42.73M |
| ReconciledDepreciation | 269.56K | 257.55K | 152.94K | 77.37K |
| EBITDA | -145.42M | -96.66M | -86.56M | -54.06M |
| EBIT | -145.69M | -96.91M | -86.71M | -54.14M |
| NetInterestIncome | 5.42M | 204.02K | -39.25K | -282.50K |
| InterestExpense | 16.11K | 267.51K | ||
| NormalizedIncome | -140.06M | -98.56M | -84.57M | -51.55M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -134.22M | -100.88M | -76.33M | -42.73M |
| TotalExpenses | 145.69M | 96.91M | 86.71M | 54.14M |
| DilutedAverageShares | 54.02M | 38.39M | 33.59M | 30.41M |
| BasicAverageShares | 54.02M | 38.39M | 33.59M | 30.41M |
| DilutedEPS | -2.48 | -2.63 | -2.27 | -1.40 |
| BasicEPS | -2.48 | -2.63 | -2.27 | -1.40 |
| DilutedNIAvailtoComStockholders | -134.22M | -100.88M | -76.33M | -42.73M |
| NetIncomeCommonStockholders | -134.22M | -100.88M | -76.33M | -42.73M |
| NetIncome | -134.22M | -100.88M | -76.33M | -42.73M |
| NetIncomeIncludingNoncontrollingInterests | -134.22M | -100.88M | -76.33M | -42.73M |
| NetIncomeContinuousOperations | -134.22M | -100.88M | -76.33M | -42.73M |
| TaxProvision | 1.83M | 1.05M | 679.09K | 70.12K |
| PretaxIncome | -132.40M | -99.83M | -75.65M | -42.66M |
| OtherIncomeExpense | 7.87M | -3.12M | 11.10M | 11.76M |
| GainOnSaleOfSecurity | 7.87M | -3.12M | 11.10M | 11.76M |
| NetNonOperatingInterestIncomeExpense | 5.42M | 204.02K | -39.25K | -282.50K |
| TotalOtherFinanceCost | -5.42M | -204.02K | 39.25K | 282.50K |
| InterestExpenseNonOperating | 16.11K | 267.51K | ||
| OperatingIncome | -145.69M | -96.91M | -86.71M | -54.14M |
| OperatingExpense | 145.69M | 96.91M | 86.71M | 54.14M |
| ResearchAndDevelopment | 98.56M | 65.58M | 57.38M | 35.79M |
| SellingGeneralAndAdministration | 47.12M | 31.34M | 29.34M | 18.35M |
| GeneralAndAdministrativeExpense | 47.12M | 31.34M | 29.34M | 18.35M |
| OtherGandA | 28.24M | 18.02M | 15.85M | 5.67M |
| InsuranceAndClaims | 6.03M | 6.44M | 5.65M | |
| SalariesAndWages | 18.88M | 13.31M | 13.48M | 7.03M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 54.38M | 52.29M | 33.82M | 33.15M |
| ShareIssued | 54.38M | 52.29M | 33.82M | 33.15M |
| TotalDebt | 861.47K | 238.91K | 436.82K | 250.18K |
| TangibleBookValue | 267.76M | 384.05M | 149.26M | 204.95M |
| InvestedCapital | 267.76M | 384.05M | 149.26M | 204.95M |
| WorkingCapital | 266.44M | 383.25M | 148.62M | 204.58M |
| NetTangibleAssets | 267.76M | 384.05M | 149.26M | 204.95M |
| CapitalLeaseObligations | 861.47K | 238.91K | 436.82K | 250.18K |
| CommonStockEquity | 267.76M | 384.05M | 149.26M | 204.95M |
| TotalCapitalization | 267.76M | 384.05M | 149.26M | 204.95M |
| TotalEquityGrossMinorityInterest | 267.76M | 384.05M | 149.26M | 204.95M |
| StockholdersEquity | 267.76M | 384.05M | 149.26M | 204.95M |
| GainsLossesNotAffectingRetainedEarnings | 39.85M | 27.88M | 20.21M | 9.80M |
| OtherEquityAdjustments | 39.71M | 27.89M | 20.17M | 9.77M |
| ForeignCurrencyTranslationAdjustments | 137.73K | -14.58K | 43.29K | 25.93K |
| RetainedEarnings | -402.26M | -265.92M | -164.19M | -87.57M |
| AdditionalPaidInCapital | 623.64M | 615.81M | 289.18M | 278.74M |
| CapitalStock | 6.53M | 6.27M | 4.06M | 3.98M |
| CommonStock | 6.53M | 6.27M | 4.06M | 3.98M |
| TotalLiabilitiesNetMinorityInterest | 23.61M | 14.65M | 18.47M | 7.14M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 639.04K | 43.56K | 249.42K | 150.75K |
| OtherNonCurrentLiabilities | -1.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 639.04K | 43.56K | 249.42K | 150.75K |
| LongTermCapitalLeaseObligation | 639.04K | 43.56K | 249.42K | 150.75K |
| CurrentLiabilities | 22.97M | 14.60M | 18.22M | 6.99M |
| CurrentDebtAndCapitalLeaseObligation | 222.43K | 195.34K | 187.40K | 99.43K |
| CurrentCapitalLeaseObligation | 222.43K | 195.34K | 187.40K | 99.43K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 7.83M | 5.89M | 2.97M | 1.46M |
| PayablesAndAccruedExpenses | 14.93M | 8.52M | 15.07M | 5.43M |
| CurrentAccruedExpenses | 9.76M | 5.18M | 7.92M | 2.81M |
| Payables | 5.16M | 3.34M | 7.15M | 2.62M |
| TotalTaxPayable | 601.25K | 429.92K | 1.17M | 491.22K |
| AccountsPayable | 4.56M | 2.91M | 5.98M | 2.13M |
| TotalAssets | 291.37M | 398.69M | 167.73M | 212.09M |
| TotalNonCurrentAssets | 1.96M | 843.10K | 886.24K | 523.40K |
| NonCurrentDeferredAssets | 474.35K | 387.53K | 259.80K | 172.05K |
| NonCurrentDeferredTaxesAssets | 474.35K | 387.53K | 259.80K | 172.05K |
| NetPPE | 1.48M | 455.57K | 626.44K | 351.35K |
| AccumulatedDepreciation | -220.14K | -125.37K | -65.53K | -26.61K |
| GrossPPE | 1.70M | 580.94K | 691.97K | 377.95K |
| OtherProperties | 1.70M | 580.94K | 691.97K | 377.95K |
| CurrentAssets | 289.42M | 397.85M | 166.85M | 211.57M |
| OtherCurrentAssets | 620.82K | 582.59K | 5.70K | |
| PrepaidAssets | 5.75M | 4.96M | 4.04M | 1.51M |
| Receivables | 2.94M | 1.04M | 382.47K | 700.08K |
| TaxesReceivable | 2.94M | 1.04M | 382.47K | 691.63K |
| AccountsReceivable | 0.00 | 8.45K | ||
| CashCashEquivalentsAndShortTermInvestments | 280.73M | 391.23M | 161.84M | 209.35M |
| CashAndCashEquivalents | 280.73M | 391.23M | 161.84M | 209.35M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -120.67M | -93.14M | -67.29M | -44.73M |
| RepaymentOfDebt | -159.66K | -220.51K | -119.53K | 0.00 |
| IssuanceOfCapitalStock | 2.24M | 342.91M | 9.61M | 156.83M |
| CapitalExpenditure | -538.09K | -89.98K | -124.30K | -130.03K |
| EndCashPosition | 280.73M | 391.23M | 161.84M | 209.35M |
| BeginningCashPosition | 391.23M | 161.84M | 209.35M | 98.63M |
| EffectOfExchangeRateChanges | 7.49M | -2.86M | 11.12M | 11.78M |
| ChangesInCash | -117.99M | 232.25M | -58.64M | 98.94M |
| FinancingCashFlow | 2.68M | 325.39M | 8.65M | 143.67M |
| CashFlowFromContinuingFinancingActivities | 2.68M | 325.39M | 8.65M | 143.67M |
| NetOtherFinancingCharges | 592.00K | -17.30M | -839.97K | -13.15M |
| NetCommonStockIssuance | 2.24M | 342.91M | 9.61M | 156.83M |
| CommonStockIssuance | 2.24M | 342.91M | 9.61M | 156.83M |
| NetIssuancePaymentsOfDebt | -159.66K | -220.51K | -119.53K | 0.00 |
| NetLongTermDebtIssuance | -159.66K | -220.51K | -119.53K | 0.00 |
| LongTermDebtPayments | -159.66K | -220.51K | -119.53K | 0.00 |
| InvestingCashFlow | -538.09K | -89.98K | -124.30K | -130.03K |
| CashFlowFromContinuingInvestingActivities | -538.09K | -89.98K | -124.30K | -130.03K |
| NetPPEPurchaseAndSale | -538.09K | -89.98K | -124.30K | -130.03K |
| PurchaseOfPPE | -538.09K | -89.98K | -124.30K | -130.03K |
| OperatingCashFlow | -120.13M | -93.05M | -67.16M | -44.60M |
| CashFlowFromContinuingOperatingActivities | -120.13M | -93.05M | -67.16M | -44.60M |
| TaxesRefundPaid | -2.77M | -1.11M | -182.82K | -27.61K |
| InterestReceivedCFO | 5.42M | 237.04K | ||
| InterestPaidCFO | -144.24K | -267.70K | ||
| ChangeInWorkingCapital | 5.89M | -5.86M | 8.38M | 1.58M |
| ChangeInOtherCurrentAssets | -136.35K | -953.86K | -2.51M | 239.88K |
| ChangeInPayablesAndAccruedExpense | 6.06M | -4.87M | 10.57M | 1.47M |
| ChangeInAccruedExpense | 4.41M | -695.75K | 6.66M | -196.75K |
| ChangeInPayable | 1.65M | -4.17M | 3.91M | 1.66M |
| ChangeInReceivables | -34.32K | -41.05K | 317.61K | -130.50K |
| OtherNonCashItems | -5.42M | -204.02K | 39.25K | 267.70K |
| StockBasedCompensation | 16.21M | 10.66M | 11.35M | 8.20M |
| DepreciationAmortizationDepletion | 269.56K | 257.55K | 152.94K | 77.37K |
| DepreciationAndAmortization | 269.56K | 257.55K | 152.94K | 77.37K |
| Depreciation | 269.56K | 257.55K | 152.94K | 77.37K |
| OperatingGainsLosses | -7.33M | 2.79M | -11.10M | -11.76M |
| NetForeignCurrencyExchangeGainLoss | -7.33M | 2.79M | -11.10M | -11.76M |
| NetIncomeFromContinuingOperations | -132.40M | -99.83M | -75.65M | -42.66M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for PHVS
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|